RARE-04. TARGETED TREATMENT OF PAPILLARY CRANIOPHARYNGIOMAS HARBORING BRAFV600E MUTATIONS

ABSTRACT: Abstract Craniopharyngiomas are surgically challenging brain tumors. Postoperatively, quality of life is often significantly impaired due to neurological and endocrinological complications. Currently, FDA approved systemic treatments are not available for patients in whom craniopharyngiomas recur after surgery and radiation. Papillary craniopharyngiomas are characterized by the presence of BRAFV600E mutations. To date, five case reports have been published on the treatment of BRAFV600E mutant papillary craniopharyngiomas with BRAF and/or MEK inhibitors. In this presentation, authors from all five previously published reports share their collective experience and provide updated follow-up on their patients, thus generating an overview of all currently available information on targeted thera

SUBMITTER: Juratli T 

PROVIDER: S-EPMC6847219 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature